ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have …
The recommended dosage of ENHERTU is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21 -day cycle) until disease progression or unacceptable toxicity. …
ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) - AstraZeneca US
Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Patient Website
ENHERTU is a prescription medicine used to treat adults who have: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has …
ENHERTU as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received at least one …
ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as …
The recommended dose of ENHERTU is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21 day cycle) until disease progression or unacceptable toxicity. Do not substitute …
Enhertu (Daiichi Sankyo Inc.): FDA Package Insert
Apr 10, 2024 · ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) …
ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the …
- Some results have been removed